Cargando…
Discovery of Nanomolar-Affinity Pharmacological Chaperones Stabilizing the Oncogenic p53 Mutant Y220C
[Image: see text] The tumor suppressor protein p53 is inactivated in the majority of human cancers and remains a prime target for developing new drugs to reactivate its tumor suppressing activity for anticancer therapies. The oncogenic p53 mutant Y220C accounts for approximately 125,000 new cancer c...
Autores principales: | Stephenson Clarke, Joseph R., Douglas, Leon R., Duriez, Patrick J., Balourdas, Dimitrios-Ilias, Joerger, Andreas C., Khadiullina, Raniya, Bulatov, Emil, Baud, Matthias G. J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Chemical Society
2022
|
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9667543/ https://www.ncbi.nlm.nih.gov/pubmed/36407959 http://dx.doi.org/10.1021/acsptsci.2c00164 |
Ejemplares similares
-
Key Players in the Mutant p53 Team: Small Molecules, Gene Editing, Immunotherapy
por: Chasov, Vitaly, et al.
Publicado: (2020) -
Assessment of Thermal Stability of Mutant p53 Proteins via Differential Scanning Fluorimetry
por: Khadiullina, Raniya, et al.
Publicado: (2022) -
Therapeutic Editing of the TP53 Gene: Is CRISPR/Cas9 an Option?
por: Mirgayazova, Regina, et al.
Publicado: (2020) -
Promising New Tools for Targeting p53 Mutant Cancers: Humoral and Cell-Based Immunotherapies
por: Chasov, Vitaly, et al.
Publicado: (2021) -
Novel Isatin-based activator of p53 transcriptional functions in tumor cells
por: Mirgayazova, Regina, et al.
Publicado: (2019)